Keep up with what’s happening at Idera Pharmaceuticals.
IMO-2125 Advances to Phase 2 Clinical Trial in PD-1 Refractory Melanoma CAMBRIDGE, Mass. and… Read more
Antisense Pioneer and Idera Founder Dr. Sudhir Agrawal Set to Retire CAMBRIDGE, Mass. and EXTON,… Read more
All objectives successfully met in Phase 1 portion of combination trial and the company is now… Read more